Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time.

Biotechnology

Education

Parthenon Therapeutics

Laurent Audoly

Christopher O’donnell

Irena Lerentracht Webster

Xinwei Sher

Paula Bucko

Joshua Merritt

Yan Qin

Ryan Newton

Fredrick Gootkind

Heather Condurso

Amy Mueller

Ziyin Wang

Tom McCaughtry

Thomas Schürpf

Peter Cincotta

Marianna Murphy

Lisa Gaynes

Susan G. MacDonald

Joseph Paul Eder

The Leadership Team at Parthenon Therapeutics is responsible for driving the strategic direction of the company in developing innovative anti-cancer therapies. Comprising experts in clinical sciences, translational medicine, research, and operational strategy, the team collaborates to oversee drug development initiatives, ensure alignment with scientific goals, and optimize the progression of therapeutic candidates like PRTH-101 towards clinical implementation, ultimately enhancing patient outcomes.

Leadership Team

Scientific Team

Clinical and Medical Team

��

Leadership Team

About

Team members

Other teams at Parthenon Therapeutics

Scientific Team

Clinical and Medical Team

��������

Leadership Team

About

Team members

Other teams at Parthenon Therapeutics

Scientific Team

Clinical and Medical Team

��